Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

<ul>
<li>We analyse the changes of A/H premium on 134 stocks over the last week. </li>
<li>Consumer staple sector led the A/H increase which was due to Lanzhou Zhuangyuan Pasture, while utilities saw the biggest A/H premium decline among sectors. </li>
<li>We highlight stocks at 52 week high of A/H premium: Tigermed, Zoomlion, Flat Glass, Baiyunshan, Hepalink. Many of these names are in the health care sector. </li>
</ul>


We analyse the changes of A/H premium on 134 stocks over the last week. 
Consumer staple sector led the A/H increase which was due to Lanzhou Zhuangyuan Pasture, while utilities saw the biggest A/H premium decline among sectors. 
We highlight stocks at 52 week high of A/H premium: Tigermed, Zoomlion, Flat Glass, Baiyunshan, Hepalink. Many of these names are in the health care sector. 


A/H Premium Weekly: Tigermed, Zoomlion, Flat Glass, Baiyunshan, Hepalink at 52w High

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Bottom-Up

Sino Biopharmaceutical / Equity Bottom-Up

<ul>
<li>We analyzed the business performance and short-term catalyst for <a href="https://www.smartkarma.com/entities/sino-biopharmaceutical" target="_blank" data-smartkarma-citation="entities:230:1" rel="noopener">Sino Biopharmaceutical (1177 HK),</a> and investors could decide whether to take advantage of it or not.</li>
<li>We also analyzed the concerns about the Company as well as our insights on the valuation of biopharmaceutical companies.</li>
<li>Based on our analysis, we are conservative about the Company’s outlook at the current stage.</li>
</ul>


We analyzed the business performance and short-term catalyst for Sino Biopharmaceutical (1177 HK), and investors could decide whether to take advantage of it or not.
We also analyzed the concerns about the Company as well as our insights on the valuation of biopharmaceutical companies.
Based on our analysis, we are conservative about the Company’s outlook at the current stage.


Sino Biopharmaceutical (1177.HK) - The Business, The Concerns, The Insights on Biopharma Valuation

Thematic (Sector/Industry)

<ul>
<li>The 2021 national medical insurance negotiation released results on December 3.</li>
<li>If the COVID virus continues to mutate in a more transmissible direction, the logic of related companies would change.</li>
<li>For those new IPOs that fell on debut, the current "cold winter" is a rational return of the crazy healthcare investment capital market since 2019.</li>
</ul>


The 2021 national medical insurance negotiation released results on December 3.
If the COVID virus continues to mutate in a more transmissible direction, the logic of related companies would change.
For those new IPOs that fell on debut, the current "cold winter" is a rational return of the crazy healthcare investment capital market since 2019.


China Healthcare Weekly (Dec.3)-2021 Insurance Negotiation Results,new COVID Virus,a Rational Return

Equity Capital Markets

<ul>
<li>Even if the biopharmaceutical enterprises become gradually mature in each part of the development process, they still have to face the final test - the commercialization.</li>
<li>If compare BeiGene’s product revenue from 2017 to 2021Q3 and the related investment during the same period, the situation was not satisfactory. The internationalization may also not meet the expectation.</li>
<li>We hope that the IPO in the SSE STAR Market would not be "the last hurrah" for BeiGene, because what BeiGene's future performance represents means a lot.</li>
</ul>


Even if the biopharmaceutical enterprises become gradually mature in each part of the development process, they still have to face the final test - the commercialization.
If compare BeiGene’s product revenue from 2017 to 2021Q3 and the related investment during the same period, the situation was not satisfactory. The internationalization may also not meet the expectation.
We hope that the IPO in the SSE STAR Market would not be "the last hurrah" for BeiGene, because what BeiGene's future performance represents means a lot.


Pre-IPO BeiGene Ltd - The Future Performance Means a Lot

<ul>
<li>As this year's policy risks gradually removed, after entering Q4, the healthcare sector has entered the range of investment.</li>
<li>Recently, the National Development and Reform Commission issued the “Notice on the implementation plan of promoting high-quality development of API industry”, indicating related opportunities.</li>
<li>The Beijing Stock Exchange (BSE) officially opened last week. In the field of healthcare, there are ten related companies would be listed in BSE.</li>
</ul>


As this year's policy risks gradually removed, after entering Q4, the healthcare sector has entered the range of investment.
Recently, the National Development and Reform Commission issued the “Notice on the implementation plan of promoting high-quality development of API industry”, indicating related opportunities.
The Beijing Stock Exchange (BSE) officially opened last week. In the field of healthcare, there are ten related companies would be listed in BSE.


China Healthcare Weekly (Nov.19) - Q4 Healthcare Rebound, New Policy on API, Beijing Stock Exchange

China

Shanghai Junshi Biosciences Co., Ltd. operates as a biopharmaceutical company. The Company develops and sells small molecule drugs, antibody drug conjugates, and other products. Shanghai Junshi Biosciences markets its products worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Shanghai Junshi Biosciences (1877 HK)

A/H Premium Weekly: Tigermed, Zoomlion, Flat Glass, Baiyunshan, Hepalink at 52w High

We look at the changes in A/H premium in the last week. We highlight consumer staple sector and utilities sector, and stocks including Tigermed,...

Ke Yan, CFA, FRM

Sino Biopharmaceutical (1177.HK) - The Business, The Concerns, The Insights on Biopharma Valuation

This article analyzed Sino Biopharmaceutical in terms of the business performance, short-term catalyst, concerns about the outlook, and insights on...

Xinyao (Criss) Wang

China Healthcare Weekly (Dec.3)-2021 Insurance Negotiation Results,new COVID Virus,a Rational Return

This article analyzed the 2021 national medical insurance negotiation results, the change in logic of valuation due to the new COVID virus, and a...

Xinyao (Criss) Wang

Pre-IPO BeiGene Ltd - The Future Performance Means a Lot

The article analyzed the commercialization performance vs the investment,the concerns on internationalization based on license-out mode and the...

Xinyao (Criss) Wang

China Healthcare Weekly (Nov.19) - Q4 Healthcare Rebound, New Policy on API, Beijing Stock Exchange

The article analyzed the investment logic and opportunities in healthcare in Q4, the new policy of API industry and potential trend, as well as the...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)